Clinical and inflammation marker features of cancer patients with COVID-19: data of Istanbul, Turkey multicenter cancer patients (2020–2022)

References

• Arslanoğlu E, Işık ME, Kara KA, et al. Surgical approach and management strategies in a pediatric cardiovascular surgery clinic during the COVID-19 outbreak. Braz J Cardiovasc Surg. 2022;37(4):466–471. doi: 10.21470/1678-9741-2020-0614.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Coronavirus (COVID-19) Dashboard; [cited 2022 Aug 06]. Available from: https://covid19.who.int/.
   Google Scholar
• Ministry of Health. Republic of Turkey. General Coronavirus Table; [cited 2022 Aug 07]. Available from: https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html.
   Google Scholar
• Özdemir N, Dizdar Ö, Yazıcı O, et al. Clinical features and outcomes of COVID‐19 in patients with solid tumors: Turkish National Registry Data. Int J Cancer. 2021;148(10):2407–2415. doi: 10.1002/ijc.33426.
   PubMed Web of Science ®Google Scholar
• Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi: 10.1016/S1470-2045(20)30096-6.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Draft landscape of COVID-19 candidate vaccines; [cited 2020 Oct 20]. Available from:https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
   Google Scholar
• Dooling K. 7Evidence to recommendation framework: an additional dose of mRNA COVID-19 vaccine following a primary series in immunocompromised people; 2021.
   Google Scholar
• Ariamanesh M, Porouhan P, Peyroshabany B, et al. Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy. Cancer Invest. 2022;40(1):26–34. doi: 10.1080/07357907.2021.1992420.
   PubMed Web of Science ®Google Scholar
• Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133–1140. doi: 10.1001/jamaoncol.2021.2155.
   PubMed Web of Science ®Google Scholar
• Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, South Africa. Int J Infect Dis. 2022;116:38–42. doi: 10.1016/j.ijid.2021.12.357.
   PubMed Web of Science ®Google Scholar
• Wang C, Deng R, Gou L, et al. Preliminary study to identify severe from moderate cases of COVID-19 using combined hematology parameters. Ann Transl Med. 2020;8(9):593. doi: 10.21037/atm-20-3391.
   PubMed Web of Science ®Google Scholar
• Xia W, Tan Y, Hu S, et al. Predictive value of systemic immune-inflammation index and neutrophil-to-lymphocyte ratio in patients with severe COVID-19. Clin Appl Thromb Hemost. 2022;28:10760296221111391. doi: 10.1177/10760296221111391.
   Web of Science ®Google Scholar
• Hamad DA, Aly MM, Abdelhameid MA, et al. Combined blood indexes of systemic inflammation as a mirror to admission to intensive care unit in COVID-19 patients: a multicentric study. J Epidemiol Glob Health. 2022;12(1):64–73. doi: 10.1007/s44197-021-00021-5.
   PubMed Web of Science ®Google Scholar
• Paliogiannis P, Zinellu A, Scano V, et al. Laboratory test alterations in patients with COVID-19 and non COVID-19 interstitial pneumonia: a preliminary report. J Infect Dev Ctries. 2020;14(7):685–690. doi: 10.3855/jidc.12879.
   PubMed Web of Science ®Google Scholar
• Paliogiannis P, Putzu C, Cortinovis D, et al. Blood cell count indexes of systemic inflammation as predictive biomarkers of immunotherapy outcomes in advanced non-small-cell lung cancer. Cancer Immunol Immunother. 2018;67(9):1349–1353. doi: 10.1007/s00262-018-2182-4.
   PubMed Web of Science ®Google Scholar
• Li S, Lan X, Gao H, et al. Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection. J Cancer Res Clin Oncol. 2017;143(12):2455–2468. doi: 10.1007/s00432-017-2506-3.
   PubMed Web of Science ®Google Scholar
• Chen L, Kong X, Wang Z, et al. Pretreatment systemic inflammation response index in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator. Cancer Manag Res. 2020;12:1543–1567. doi: 10.2147/CMAR.S235519.
   PubMed Web of Science ®Google Scholar
• Nooh HA, Abdellateif MS, Refaat L, et al. The role of inflammatory indices in the outcome of COVID-19 cancer patients. Med Oncol. 2022;39(1):14. doi: 10.1007/s12032-021-01605-8.
   Web of Science ®Google Scholar
• Stringer D, Braude P, Myint PK, et al. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021;50(2):420–429. doi: 10.1093/ije/dyab012.
   PubMed Web of Science ®Google Scholar
• Chau VQ, Oliveros E, Mahmood K, et al. The imperfect cytokine storm: severe COVID-19 with ARDS in a patient on durable LVAD support. JACC Case Rep. 2020;2(9):1315–1320. doi: 10.1016/j.jaccas.2020.04.001.
   PubMedGoogle Scholar
• Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicenter, retrospective, cohort study. Lancet Oncol. 2020;21(7):904–913. doi: 10.1016/S1470-2045(20)30310-7.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan. China. JAMA. 2020;323(11):1061–1069. doi: 10.1001/jama.2020.1585.
   PubMed Web of Science ®Google Scholar
• Ministry of Health. Republic of Turkey. Covid-19 Information Page; [cited 2022 Nov 21]. Available from: https://covid19asi.saglik.gov.tr/.
   Google Scholar
• Peng J, Qi D, Yuan G, et al. Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): a multicenter, cross-sectional study. J Clin Lab Anal. 2020;34(10):e23475. doi: 10.1002/jcla.23475.
   PubMed Web of Science ®Google Scholar
• Dettorre GM, Dolly S, Loizidou A, et al. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid ınflammatory score. J Immunother Cancer. 2021;9(3):e002277. doi: 10.1136/jitc-2020-002277.
   PubMed Web of Science ®Google Scholar
• Fois AG, Paliogiannis P, Scano V, et al. The systemic inflammation index on admission predicts in-hospital mortality in COVID-19 patients. Molecules. 2020;25(23):5725. doi: 10.3390/molecules25235725.
   PubMed Web of Science ®Google Scholar
• Sezen Aİ, Yaşar KK. Predictive role of NLR, SII, and PLR in COVID-19 patient mortality and disease severity. Archives of. acmr. 2022;3(1):43–50. doi: 10.47482/acmr.2022.47.
   Google Scholar
• Citu C, Gorun F, Motoc A, et al. The predictive role of NLR, d-NLR, MLR, and SIRI in COVID-19 mortality. Diagnostics. 2022;12(1):122. doi: 10.3390/diagnostics12010122.
   Web of Science ®Google Scholar
• Zheng Y, Zhang Y, Chi H, et al. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study. Clin Chem Lab Med. 2020;58(7):1106–1115. (CCLM). doi: 10.1515/cclm-2020-0377.
   PubMed Web of Science ®Google Scholar
• Ghazi B, El Azhary K, Kantri A, et al. Neutrophilia during hospitalization predicts ARDS and risk of death in COVID-19 patients; 2022.
   Google Scholar
• Lee RJ, Wysocki O, Bhogal T, et al. Longitudinal characterisation of hematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome. ESMO Open. 2021;6(1):100005. doi: 10.1016/j.esmoop.2020.100005.
   PubMed Web of Science ®Google Scholar
• Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955. doi: 10.1371/journal.pone.0241955.
   PubMed Web of Science ®Google Scholar
• Wong YNS, Sng CC, Ottaviani D, et al. Systemic anti-cancer therapy and metastatic cancer are independent mortality risk factors during two UK waves of the COVID-19 pandemic at university college london hospital. Cancers. 2021;13(23):6085. doi: 10.3390/cancers13236085.
   PubMed Web of Science ®Google Scholar
• Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi: 10.1016/j.ijid.2020.03.017.
   PubMed Web of Science ®Google Scholar
• Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775.
   PubMed Web of Science ®Google Scholar
• Fu C, Stoeckle JH, Masri L, et al. COVID‐19 outcomes in hospitalized patients with active cancer: experiences from a major New York City health care system. Cancer. 2021;127(18):3466–3475. doi: 10.1002/cncr.33657
   PubMed Web of Science ®Google Scholar
• Garassino MC, Whisenant JG, Huang LC, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7):914–922. doi: 10.1016/S1470-2045(20)30314-4.
   PubMed Web of Science ®Google Scholar
• Robilotti EV, Babady NE, Mead PA, et al. Determinants of severity in cancer patients with COVID-19 illness. Nat Med. 2020;26(8):1218–1223. doi: 10.1038/s41591-020-0979-0.
   PubMed Web of Science ®Google Scholar
• Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926. doi: 10.1016/S0140-6736(20)31173-9.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lu H, Wang W, et al. Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies. Expert Rev Anticancer Ther. 2021;21(1):107–119. doi: 10.1080/14737140.2021.1837628.
   PubMed Web of Science ®Google Scholar
• Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020;64(12):e01897–20. doi: 10.1128/AAC.01897-20.
   PubMed Web of Science ®Google Scholar
• Bosaeed M, Alharbi A, Mahmoud E, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicenter, placebo-controlled clinical trial. Clin Microbiol Infect. 2022;28(4):602–608. doi: 10.1016/j.cmi.2021.12.026.
   PubMed Web of Science ®Google Scholar
• Shenoy S, Munjal S, Youha SA, et al. Favipiravir In Adults with Moderate to Severe COVID-19: a Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial. medRxiv, 2021;11.08.21265884.
   Google Scholar